Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05887713 · ClinicalTrials.gov registry record · NA

Novel Mental Health Therapies to Improve Military Readiness

A NA study of Anxiety and Cognitive Behavioral Therapy, sponsored by David Moss.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT05887713 is a NA study of Anxiety and Cognitive Behavioral Therapy that is actively recruiting participants, run by David Moss. The registered enrollment target is 160 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05887713, a NA study of Anxiety and Cognitive Behavioral Therapy, is actively recruiting participants, sponsored by David Moss.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES.

Interventions

  • DEVICE Sham Comparator
  • DEVICE Experimental: Alpha-Stim 100

Study Locations (1)

Nevada

  • Mike O'Callaghan Military Medical Center - Nellis Air Force Base

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2024-01-01
Est. Completion 2025-12
Phase NA

Sponsor

David Moss

7 total trials

What the Registry Record Tells You About NCT05887713

The ClinicalTrials.gov registry entry for NCT05887713 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (64% lower). The listed sponsor is David Moss, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.

NCT05887713 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT05887713 about?

NCT05887713 is a clinical study titled "Novel Mental Health Therapies to Improve Military Readiness". To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES.

What is the current status of trial NCT05887713?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2024-01-01. Estimated completion is 2025-12.

What conditions does trial NCT05887713 study?

This clinical trial studies the following conditions: Anxiety, Cognitive Behavioral Therapy, Heart Rate Variability, Alpha Stim, Cranial Electrotherapy Stimulation.

What interventions are being tested in trial NCT05887713?

The interventions under investigation include: Sham Comparator (DEVICE), Experimental: Alpha-Stim 100 (DEVICE).

Who is sponsoring clinical trial NCT05887713?

This trial is sponsored by David Moss, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05887713 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.